Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

about

Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence

P2860

Q57145115-B90F9F7A-B393-4B45-868D-026950DBC8FA

P2860

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

Item

http://www.wikidata.org/entity/Q48111916

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@en

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@nl

type

Item

label

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@en

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@nl

prefLabel

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@en

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

@nl

P1476

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

@en

P2093

Astrid Louise Løvlie

http://www.w3.org/2001/XMLSchema#string

Ellen J Amundsen

http://www.w3.org/2001/XMLSchema#string

Hilde Kløvstad

http://www.w3.org/2001/XMLSchema#string

Hinta Meijerink

http://www.w3.org/2001/XMLSchema#string

Olav Dalgard

http://www.w3.org/2001/XMLSchema#string

Richard White

http://www.w3.org/2001/XMLSchema#string

P2860

Q28066258

Drugs for Chronic Hepatitis C Infection: Cost-Effectiveness Analysis

Gender differences in mortality and risk factors in a 13-year cohort study of street-recruited injecting drug users

No strategy to meet the HCV epidemic

The history of the "natural history" of hepatitis C (1968-2009).

Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another.

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

Health-state utilities in liver disease: a systematic review.

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010.

P2888

s40273-017-0604-3

P304

591-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-017-0604-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Torbjørn Wisløff

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29396744

http://www.w3.org/2001/XMLSchema#string

P932

5906515

http://www.w3.org/2001/XMLSchema#string

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

about

P2860

P2860

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932